![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase III Randomized Study of Triptorelin for Prevention of Chemotherapy-Induced Menopause in Premenopausal Women Undergoing Adjuvant Chemotherapy for Previously Resected Stage I-III Breast Cancer
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outcomes Outline Trial Contact Information Registry Information
Alternate Title
Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
Phase III
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
Biomarker/Laboratory analysis, Supportive care, Treatment
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
Completed
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
18 to 45
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
Other
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
GIM-6 GIM-PROMISE, EU-20606, GIM-5104, NCT00311636
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives Primary - Evaluate the incidence of chemotherapy-induced early menopause in premenopausal women undergoing adjuvant chemotherapy in combination with vs without triptorelin for previously resected stage I-III breast cancer.
Secondary - Compare the toxicity of adjuvant chemotherapy and triptorelin vs adjuvant chemotherapy alone.
Entry Criteria Disease Characteristics:
- Histologically or cytologically confirmed breast cancer resected at time of original diagnosis
- Candidate for 1 of the following adjuvant chemotherapy regimens:
- FEC (fluorouracil, epirubicin hydrochloride, and cyclophosphamide) every 21 or 28 days
- CMF (cyclophosphamide, methotrexate, and fluorouracil) every 28 days
- A→CMF (doxorubicin hydrochloride followed by CMF)
- EC→P (epirubicin hydrochloride and cyclophosphamide every 21 days followed by paclitaxel every 21 days)
- FEC→P (FEC every 21 days followed by paclitaxel every 21 days)
- EC→D (EC every 21 days followed by docetaxel every 21 days)
- AC (doxorubicin hydrochloride and cyclophosphamide) every 21 days
- AC→P (AC every 21 days followed by paclitaxel every 21 days)
- E→CMF (epirubicin hydrochloride followed by CMF every 28 days)
- No evidence of metastases or localized or distant recurrence
- Investigation to exclude metastases required for any suspicious manifestation
- Premenopausal, defined as the presence of active menstrual cycles or normal menses within six weeks before initiation of chemotherapy
- Hormone receptor status not specified
Prior/Concurrent Therapy:
- See Disease Characteristics
- No prior chemotherapy and/or radiotherapy for cancer or non-neoplastic disease
- No other concurrent hormonal therapy except for tamoxifen
Patient Characteristics:
- Female
- No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or adequately treated in situ carcinoma of the cervix
- No history of noncompliance to medical regimens or patients who are considered potentially unreliable
- Not pregnant or nursing
- Negative pregnancy test
Expected Enrollment 280A total of 280 patients will be accrued for this study. Outcomes Primary Outcome(s)Chemotherapy-induced early menopause as measured by follicle-stimulating hormone, 17 beta estradiol levels, and menstrual activity resumption at 1 year following the completion of chemotherapy
Secondary Outcome(s)Toxicity as measured by Common Toxicity Criteria at each chemotherapy course
Outline This is a prospective, open-label, multicenter, randomized study. Patients are randomized to 1 of 2 treatment arms. Patients undergo menopausal status assessment, using follicle-stimulating hormone, luteinizing hormone, and estradiol as biochemical markers, at baseline and 3, 6, 9, and 12 months after the last course of chemotherapy. After completion of study treatment, patients are followed at 3, 6, 9, and 12 months.
Trial Contact Information
Trial Lead Organizations Gruppo Italiano Mammella ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | Lucia Del Mastro, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | Prevention of Chemotherapy-induced Menopause by Temporary Ovarian Suppression with Triptorelin Vs. Control in Young Breast Cancer Patients. A Randomized Phase III Multicenter Study [PROMISE] | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 2003-09-05 | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | Trial Completion Date | | 2008-01-21 | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00311636 | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 2006-02-07 | ![](https://webarchive.library.unt.edu/eot2008/20081020104733im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2008-04-06 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |